DnB Asset Management AS grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 19.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 21,860 shares of the company’s stock after acquiring an additional 3,500 shares during the period. DnB Asset Management AS’s holdings in IDEXX Laboratories were worth $3,418,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in IDXX. D.A. Davidson & CO. raised its position in IDEXX Laboratories by 160.4% in the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after acquiring an additional 385 shares during the period. Sun Life Financial INC raised its position in IDEXX Laboratories by 9,085.7% in the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock worth $104,000 after acquiring an additional 636 shares during the period. BB&T Investment Services Inc. bought a new position in IDEXX Laboratories in the second quarter worth approximately $104,000. Zions Bancorporation bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $162,000. Finally, BB&T Securities LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $213,000. Institutional investors and hedge funds own 86.61% of the company’s stock.
Several analysts have recently commented on the stock. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective on the stock in a research report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. BidaskClub upgraded shares of IDEXX Laboratories from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Finally, Canaccord Genuity restated a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $173.67.
In related news, CEO Jonathan W. Ayers sold 2,160 shares of the firm’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $167.03, for a total transaction of $360,784.80. Following the completion of the transaction, the chief executive officer now directly owns 1,077,112 shares of the company’s stock, valued at $179,910,017.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the transaction, the chief executive officer now directly owns 1,064,573 shares of the company’s stock, valued at $163,678,098.75. The disclosure for this sale can be found here. Insiders have sold 130,160 shares of company stock valued at $20,019,685 over the last ninety days. 2.77% of the stock is currently owned by corporate insiders.
Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $173.24 on Friday. The company has a market cap of $15,100.00, a price-to-earnings ratio of 56.25, a PEG ratio of 2.31 and a beta of 0.42. IDEXX Laboratories, Inc. has a 52-week low of $116.54 and a 52-week high of $173.82. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. The firm had revenue of $492.00 million for the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The company’s revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm earned $0.62 EPS. analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://transcriptdaily.com/2018/01/14/dnb-asset-management-as-acquires-3500-shares-of-idexx-laboratories-inc-idxx.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.